Share |

Verisante Technology, Inc. to Present at 2nd Emerging Medical Technologies (EMT) Summit

November 10, 2014 at 2:00 pm

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, today announced that Thomas Braun, President & CEO, will present at the upcoming Emerging Medical Technologies (EMT) Summit  in San Francisco on November 11, 2014 at the Sofitel Hotel San Francisco Bay.

On November 10 – 12th, at the Emerging Medical Technologies (EMT) Summit, active medical device venture capitalists and top business development executives from the medtech industry will be in attendance to preview CEO presentations from 75 innovative emerging medical technology companies.  They will have access there to Verisante’s management through a corporate presentation and small group meetings.

The organizer of this event is Life Science Intelligence (LSI). For more information please visit:

About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. Verisante’s Aura™ for skin cancer detection and the Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan,  Popular Science Magazine’s “Best of What’s New Award” for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. 


Company Contact:
Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 605-0507

Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top